Early impact of human papillomavirus vaccination on cervical neoplasia - Nationwide follow-up of young danish women

Journal of the National Cancer Institute

Volumn 106, Issue 3, 2014, Pages

  Baldur Felskov, Birgitte ^a   Dehlendorff, Christian ^a   Munk, Christian ^a   Kjaer, Susanne K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; ATYPIA; CANCER GRADING; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; WART VIRUS; ADOLESCENT; PAPILLOMAVIRUS INFECTION; REGISTER; RISK; SOCIAL CLASS; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; DENMARK; FEMALE; HUMANS; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REGISTRIES; RISK; SOCIAL CLASS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84898746929     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt460     Document Type: Article

References (32)

1. European Medicines Agency. European public assessment report for Cervarix. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000721/human-med-000694.jsp&mid=WC0b01ac058 001d125&murl=menus/medicines/medicines.jsp Accessed January 9, 2013.
2. European Medicines Agency. European public assessment report for Gardasil. http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000703/human-med-000805.jsp. Accessed January 9, 2013.
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
4. FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861-1868.
5. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314.
6. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
7. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123-F138.
8. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV- 16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89-99.
9. Sander BB, Rebolj M, Valentiner-Branth P, Lynge E. Introduction of human papillomavirus vaccination in Nordic countries. Vaccine. 2012;30(8):1425-1433.
10. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117(2 Suppl):S5-S10.
11. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs. 2010;70(9):1079-1098.
12. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805-814.
13. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a metaanalysis update. Int J Cancer. 2007;121(3):621-632.
14. Sundhedsstyrelsen. Reduktion af risikoen for livmoderhalskræft ved vaccination mod humant papillomvirus (HPV) - en medicinsk teknologivurdering. http://www.sst.dk/publ/Publ2007/MTV/HPV/HPV-vaccination.pdf. Accessed December 19, 2012.
15. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87(7):544-547.
16. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health. 2012;102(5):833-835.
17. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40(2):130-135.
18. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206(6):860-866.
19. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085-2092.
20. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206(11):1645-1651.
21. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31(1):109-113.
22. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013;105(7):469-474.
23. Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark [published online ahead of print July 15, 2013]. Clin Infect Dis. 2013;57(7):929-934. doi: 10.1093/cid/cit436.
24. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 Suppl):22-25.
25. Andersen JS, Olivarius NF, Krasnik A. The Danish National Health Service Register. Scand J Public Health. 2011;39(7 Suppl):34-37.
26. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 Suppl):38-41.
27. The Danish Pathology Data Bank. The Danish Pathology Data Bank. http://www.patobank.dk/. Accessed December 19, 2012.
28. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-2119.
29. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
30. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Australia: R Foundation for Statistical Computing; 2012.
31. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943.
32. Rana MM, Huhtala H, Apter D, et al. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: cancer registry-based follow-up. Int J Cancer. 2013;132(12):2833-2838.